Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Biondvax Pharma ADR (BVXV)

Biondvax Pharma ADR (BVXV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
BiondVax Pharmaceuticals (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd. Investor Brand Network - Wed Sep 6, 2023

BiondVax (NASDAQ: BVXV), a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023....

BVXV : 1.3600 (+3.82%)
BiondVax Pharmaceuticals (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs Investor Brand Network - Tue Sep 5, 2023

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting...

BVXV : 1.3600 (+3.82%)
LLY : 805.55 (-0.07%)
DICE : 47.55 (+0.06%)
BiondVax Pharmaceuticals (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17 Investor Brand Network - Mon Aug 28, 2023

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune...

BVXV : 1.3600 (+3.82%)
BiondVax Pharmaceuticals (NASDAQ: BVXV) Advances NanoAb as IL-17 Drug Candidate for Psoriasis Investor Brand Network - Fri Aug 18, 2023

Modern-day medicine has been revolutionized and personalized to cater to more specific disease characteristics. A prime example of this innovation is monoclonal antibodies (“mAbs”) and nanosized antibodies...

APGE : 57.37 (+1.90%)
BVXV : 1.3600 (+3.82%)
BiondVax Pharmaceuticals (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update Investor Brand Network - Wed Aug 16, 2023

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious...

BVXV : 1.3600 (+3.82%)
BiondVax Pharmaceuticals’ (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics Investor Brand Network - Tue Aug 15, 2023

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious...

BVXV : 1.3600 (+3.82%)
BiondVax Pharmaceuticals (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update Investor Brand Network - Mon Aug 14, 2023

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious...

BVXV : 1.3600 (+3.82%)
BiondVax Pharmaceuticals (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance Investor Brand Network - Wed Aug 2, 2023

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious...

BVXV : 1.3600 (+3.82%)
BiondVax (NASDAQ: BVXV) Leveraging NanoAb Pipeline to Target Large Markets Investor Brand Network - Fri Jul 28, 2023

BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious...

BVXV : 1.3600 (+3.82%)
M&A Activity, Sales of Anti-IL-17 Drugs Suggest Upside Potential for BiondVax Pharmaceuticals (NASDAQ: BVXV) Investor Brand Network - Wed Jul 26, 2023

According to Goldman Sachs Research, the global pharmaceutical industry is sitting on about $700 billion in dealmaking firepower, expected to fuel M&A-driven growth as companies look to revamp their intellectual...

BVXV : 1.3600 (+3.82%)
GS : 523.82 (+2.41%)
LLY : 805.55 (-0.07%)
DICE : 47.55 (+0.06%)

Barchart Exclusives

Should You Buy Meta Platforms Stock After Earnings? Barchart - 35 minutes ago
Despite crushing broader market returns in the past two years, Meta Platforms stock still trades at a reasonable valuation. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot